ACOR Acorda Therapeutics Inc.

20.00
+0.50  (3%)
Previous Close 19.50
Open 19.65
Price To book 1.38
Market Cap 934943320
Shares 46,747,166
Volume 356,405
Short Ratio 8.16
Av. Daily Volume 869,732

SEC filingsSee all SEC filings

  1. 8-K - Current report 171212596
  2. 8-K - Current report 171209692
  3. 8-K - Current report 171203859
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171184481
  5. 8-K - Current report 171163978

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 2 to be initiated by the end of 2017.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Phase 3 data due 1Q 2018. However, company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017. NDA to be refiled 4Q 2017.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  2. Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Acorda Therapeutics
  3. Acorda to Present at the Piper Jaffray Healthcare Conference
  4. ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda Therapeutics, Inc.
  5. ACOR INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Acorda Therapeutics, Inc. Investors
  6. ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Acorda Therapeutics, Inc. to Contact the Firm
  7. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
  8. Acorda shares drop 2.5% on discontinuation of Parkinson's disease drug
  9. Acorda Therapeutics scraps development of Parkinson's disease drug
  10. Acorda Discontinues Tozadenant Development Program
  11. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda Therapeutics, Inc.
  12. [$$] Clinical Development News, Nov. 13-17
  13. ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm
  14. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Acorda Therapeutics, Inc. – ACOR
  15. Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : November 17, 2017
  16. Pomerantz Law Firm Announces the Filing of a Class Action against Acorda Therapeutics, Inc. and Certain Officers – ACOR
  17. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda Therapeutics, Inc.
  18. Acorda unveils royalty transactions valued at $53 million
  19. Acorda Announces Royalty Monetization Transactions for $53 Million

SEC Filings

  1. 8-K - Current report 171212596
  2. 8-K - Current report 171209692
  3. 8-K - Current report 171203859
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171184481
  5. 8-K - Current report 171163978
  6. 8-K - Current report 171103136
  7. 8-A12B - Registration of securities [Section 12(b)] 171064461
  8. 8-K - Current report 171064460
  9. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171063767
  10. 8-K - Current report 171056160